Oxidized phospholipids are thought to promote atherogenesis by stimulating endothelial cells (ECs) to produce inflammatory cytokines, such as IL-8. In studies with mouse models, we previously demonstrated that genetic variation in inflammatory responses of endothelial cells to oxidized lipids contributes importantly to atherosclerosis susceptibility. We now show that similar variations occur in cultured aortic ECs derived from multiple heart transplant donors. These variations were stably maintained between passages and, thus, reflect either genetic or epigenetic regulatory differences. Expression array analysis of aortic EC cultures derived from 12 individuals revealed that >1,000 genes were regulated by oxidized phospholipids. We have used the observed variations in the sampled population to construct a gene coexpression network comprised of 15 modules of highly connected genes. We show that several identified modules are significantly enriched in genes for known pathways and confirm a module enriched for unfolded protein response (UPR) genes using siRNA and the UPR inducer tunicamycin. On the basis of the constructed network, we predicted that a gene of unknown function (MGC4504) present in the UPR module is a target for UPR transcriptional activator ATF4. Our data also indicate that IL-8 is present in the UPR module and is regulated, in part, by the UPR. We validate these by using siRNA. In conclusion, we show that interindividual variability can be used to group genes into pathways and predict gene-gene regulatory relationships, thus identifying targets potentially involved in susceptibility to common diseases such as atherosclerosis.genetic ͉ interleukin 8 ͉ atherosclerosis ͉ unfolded protein response ͉ network A therosclerosis, the major cause of heart disease, is characterized by the accumulation of cholesterol, inflammatory cells, smooth muscle cells, and fibrous elements beneath the endothelial cell (EC) monolayer that lines the artery wall (1). Although numerous risk factors for atherosclerosis, such as elevated blood pressure, hypercholesterolemia, and smoking, have been recognized, these factors do not alone account for the genetic contribution to risk (2). An important mechanism contributing to the recruitment of inflammatory cells in atherosclerosis is the induction of adhesion molecules, growth factors, and cytokines in vascular ECs by oxidized phospholipids, such as oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycero-phosphorylcholine (oxPAPC) derived from lipoproteins trapped in the vessel wall (3).We have previously demonstrated that ECs from different strains of mice show differences in the induction of inflammatory genes when treated with oxidized lipoproteins, and that these differences segregate with susceptibility to atherosclerosis (4, 5). Studies in human populations show significant variability in the plasma levels of inflammatory mediators associated with atherosclerosis, including IL-8 and C-reactive protein (6-8). The plasma levels of cytokines are influenced by genetic and environmenta...

Matrix GLA protein (MGP) has been identified as a calcification inhibitor in cartilage and vasculature. Part of this effect may be attributed to its influence on osteoinductive activity of bone morphogenetic protein-2 (BMP-2). To detect binding between MGP and BMP-2, we performed immunoprecipitation using MGP and BMP-2 tagged with FLAG and c-Myc. The results showed coprecipitation of BMP-2 with MGP. To quantify the effect of MGP on BMP-2 activity, we assayed for alkaline phosphatase activity and showed a dose-dependent effect. Low levels of MGP relative to BMP-2 (<1-fold excess) resulted in mild enhancement of osteoinduction, whereas intermediate levels (1-15-fold excess) resulted in strong inhibition. High levels of MGP (>15-fold excess), however, resulted in pronounced enhancement of the osteoinductive effect of BMP-2. Cross-linking studies showed that inhibitory levels of MGP abolished BMP-2 receptor binding. Immunoblotting showed a corresponding decrease in activation of Smad1, part of the BMP signaling system. Enhancing levels of MGP resulted in increased Smad1 activation. To determine the cellular localization of BMP-2 in the presence of MGP, binding assays were performed on whole cells and cellsynthesized matrix. Inhibitory levels of MGP yielded increased matrix binding of BMP-2, suggesting that MGP inhibits BMP-2 in part via matrix association. These results suggest that MGP is a BMP-2 regulatory protein. MGP1 is a small matrix protein that was initially isolated from bone and characterized by Price and Williamson (1). MGP deficiency in mice results in premature calcification in bone, calcification of normally noncalcifying cartilage, such as the trachea, and severe vascular calcification leading to premature death (2). Thus, MGP functions as a calcification inhibitor; however, its molecular mechanism is incompletely understood.MGP appears to play a role in cell differentiation. In the artery wall of the MGP knockout mouse, medial smooth muscle cells are replaced by chondrocyte-like cells undergoing endochondral ossification, and in the growth plate of growing bones, hypertrophic chondrocytes are lacking (2). Further support for an effect of MGP on cell differentiation comes from the work of Yagami et al. (3), who show that overexpression of MGP in developing limbs delays chondrocyte maturation and blocks endochondral ossification. In addition, MGP inactivation triggers mineralization in cultured hypertrophic chondrocytes but not in immature chondrocytes. This is consistent with recent data from Newman et al. (4) demonstrating that overexpression of MGP in hypertrophic chondrocytes reduces mineralization. These authors also show that MGP expression is biphasic and stage-specific during chondrocyte differentiation and that MGP has an effect on chondrocyte viability. Increased expression of MGP induces apoptosis in maturing chondrocytes, whereas decreased expression induces apoptosis in proliferative and hypertrophic chondrocytes.Previous studies from our laboratory using the multipotent cell line C3H10T1/...

Accumulation of extracellular matrix is a characteristic of diabetic nephropathy, and advanced glycation end products (AGEs) are considered to play an important role in the mechanism. To investigate the involvement of the receptor for AGE (RAGE) in upregulation of type IV collagen by AGEs, we applied the hammerhead ribozyme for targeting RAGE. We established a stable mouse mesangial cell line that produces the RAGE-specific ribozyme (Rz-RAGE). Both the RAGE mRNA and protein were decreased in the cell line. The amount of type IV collagen mRNA increased by AGEs' treatment in control cells. In contrast, the increase of type IV collagen induced by AGEs was not observed in the Rz-RAGE-producing cells. We conclude that the induction of type IV collagen by AGEs is mediated by RAGE and this mechanism could be involved in diabetic nephropathy. This study also suggested the experimental/therapeutic potential of hammerhead ribozymes.